Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

News Features

Year in Review: Low-Risk TAVR Trials Big in 2019, but QoL Data Impresses, Too

Michael O'Riordan

December 18, 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

Solid 2-Year Outcomes for Portico, With Paravalvular Leak Rare

Michael O'Riordan

November 20, 2019

News Conference News PCR London Valves 2019

Signal of Impaired Sapien XT Durability in Midterm Follow-up

Michael O'Riordan

November 20, 2019

News Conference News AHA 2019

TAVR Valve Face-off: Two French Observational Studies Suggest Inherent Differences

Yael L. Maxwell

November 18, 2019

News Daily News

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Michael O'Riordan

November 06, 2019

News Conference News TCT 2019

Predicting Final Valve Position After TAVR: Different Devices, Different Success

Michael O'Riordan

October 07, 2019

News Conference News TCT 2019

TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3

Yael L. Maxwell

September 29, 2019

Presentation TCT 2019

Deep-Dive: NEW Insights From the Evolut Low-Risk Trial

Presenter: Michael Reardon

September 26, 2019

News Conference News TCT 2019

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

Michael O'Riordan

September 25, 2019

Presentation TCT 2019

COAPT, Partner 2, and Evolut Low-Risk Trial Synopsis and What They Mean Moving Forward

Presenter: Elizabeth Perpetua

September 25, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2019

Shelley Wood

August 30, 2019

News Daily News

MIDAS Touch: Anatomic Strategy Dramatically Lowers Pacemaker Rate With Evolut Valves

Michael O'Riordan

August 29, 2019

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Caitlin E. Cox

August 21, 2019

News Daily News

Expert Consensus Gives Initial Guidance on Post-TAVR Conduction Disturbances

Yael L. Maxwell

August 20, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Industry News

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

August 16, 2019

News Daily News

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Michael O'Riordan

July 10, 2019

News Conference News TVT 2019

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Michael O'Riordan

June 20, 2019

News Conference News TVT 2019

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Michael O'Riordan

June 19, 2019

Advertisement

Year in Review: Low-Risk TAVR Trials Big in 2019, but QoL Data Impresses, Too

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Solid 2-Year Outcomes for Portico, With Paravalvular Leak Rare

Signal of Impaired Sapien XT Durability in Midterm Follow-up

TAVR Valve Face-off: Two French Observational Studies Suggest Inherent Differences

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Predicting Final Valve Position After TAVR: Different Devices, Different Success

TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3

Deep-Dive: NEW Insights From the Evolut Low-Risk Trial

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

COAPT, Partner 2, and Evolut Low-Risk Trial Synopsis and What They Mean Moving Forward

TCTMD’s Top 10 Most Popular Stories for August 2019

MIDAS Touch: Anatomic Strategy Dramatically Lowers Pacemaker Rate With Evolut Valves

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Expert Consensus Gives Initial Guidance on Post-TAVR Conduction Disturbances

FDA Expands TAVR Indication to Low-Risk Patients

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content